Apologies if this was already posted:
ESMO 2023: PSMAfore Phase 3 Trial of ... - Advanced Prostate...
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
Written by
swwags
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
If indeed apologies are required.......... Then, I apologize.......
But keep posting cause we need the information that you bring to the table.
Good Bless and keep up the good work....
Good Luck, Good Health and Good Humor.
j-o-h-n Friday 10/27/2023 2:07 PM DST
The graphics alone help explain the outcomes and dumbed this article down for me.
Not what you're looking for?
You may also like...
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer
tandem theraphy is available somewhere in Europe?
https://pubmed.ncbi.nlm.nih.gov/31758224/...
Lu-177-PSMA-I&T for low volume Metastatic Castration-Resistant Prostate Cancer
Germany recently. Is anyone familiar with Lu-177-PSMA-I&T for Metastatic Castration-Resistant...
promising against soft tissue and bone metastasis: AMG 509
https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147455-esmo-20
FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
the LU177 now available?...
Adaptive dosing: very promising results with Enzalutamide + Lutetium
https://www.urotoday.com/video-lectures/esmo-2023/video/3699-enza-p-trial-shows-promise-for-enzaluta